Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9932 USD | +1.97% | +8.36% | -29.06% |
May. 09 | Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating | MT |
May. 09 | Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-29.06% | 151M | C+ | ||
+11.60% | 106B | B+ | ||
-4.68% | 24.28B | B+ | ||
-0.82% | 21.96B | B | ||
-10.12% | 18.16B | A- | ||
-42.12% | 16.37B | A- | ||
-17.47% | 15.56B | B | ||
+2.77% | 13.63B | C+ | ||
+34.58% | 12.27B | C+ | ||
+77.64% | 8.87B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MCRB Stock
- Ratings Seres Therapeutics, Inc.